China National Logging Corporation (CNLC) is a technical service company under CNPC specializing in overseas wireline logging, mud logging, well testing, LWD/directional well and data interpretation and appraisal. To ...China National Logging Corporation (CNLC) is a technical service company under CNPC specializing in overseas wireline logging, mud logging, well testing, LWD/directional well and data interpretation and appraisal. To implement of CNPC's worldwide operational strategy, CNLC has actively sought for international business development and expanded the overseas service market in the principles of perfect services.展开更多
目的观察原发性肝癌(primary hepatocellular carcinoma,PHC)与血清25(OH)维生素D水平的相关性。方法抽取2018年8月—2020年8月莆田市第一医院PHC患者50例作为观察组,抽取同时期健康体检者50例作为对照组。检测两组血清25(OH)D3水平以...目的观察原发性肝癌(primary hepatocellular carcinoma,PHC)与血清25(OH)维生素D水平的相关性。方法抽取2018年8月—2020年8月莆田市第一医院PHC患者50例作为观察组,抽取同时期健康体检者50例作为对照组。检测两组血清25(OH)D3水平以及甲胎蛋白(alpha fetoprotein,AFP)水平。结果观察组血清25(OH)D3水平低于对照组,差异有统计学意义(P<0.05)。观察组AFP水平高于对照组,差异有统计学意义(P<0.05)。PHC血清患者25(OH)D3水平与中国肝癌分期(China live cancer staging,CNLC)、淋巴结转移有关,差异有统计学意义(P<0.05)。结论针对PHC患者,其血清25(OH)D3水平主要相关因素为CNLC分期、淋巴结转移,根据血清25(OH)D3水平可为疾病治疗及其预后评估提供依据。展开更多
Background and Aims:To validate prognostic performance of the China liver cancer(CNLC)staging system as well as to compare these parameters with those of the Barcelona Clinic Liver Cancer(BCLC)staging system for Chine...Background and Aims:To validate prognostic performance of the China liver cancer(CNLC)staging system as well as to compare these parameters with those of the Barcelona Clinic Liver Cancer(BCLC)staging system for Chinese hepatocellular carcinoma(HCC)treated with transarterial chemoembolization(TACE).Methods:This multicenter retrospective study included 1,124 patients with HCC between January 2012 and December 2020 from six Chinese hospitals.Based on overall survival(OS),the prognostic performance outcomes for the CNLC and BCLC staging systems were compared by model discrimination[C statistic and Akaike information criterion(AIC)],monotonicity of the gradient(linear trend chi-square test),homogeneity(likelihood ratio chisquare test),and calibration(calibration plots).A prospective cohort of 44 patients receiving TACE-based therapy included between January 2021 and December 2022 was used to prospectively validate the outcomes.Results:Median OS was 19.1(18.2–20.0)months,with significant differences in OS between stages defined by the CNLC and BCLC observed(p<0.001).The CNLC performed better than the BCLC regarding model discrimination(C-index:0.661 vs.0.644;AIC:10,583.28 vs.10,583.72),model monotonicity of the gradient(linear trend chi-square test:66.107 vs.57.418;p<0.001),model homogeneity(159.2 vs.158.7;p<0.001).Both staging systems had good model calibration.Similar results were observed in the prospective cohort.Conclusions:Combining model discrimination,gradient monotonicity,homogeneity,and calibration,the CNLC performed better than the BCLC for Chinese HCC patients receiving TACE.展开更多
BACKGROUNDPrimary liver cancer is the sixth most prevalent tumor and the third leading cause of cancer-relatedmortality worldwide[1]. In 2020, there were approximately 900,000 new cases of primary liver cancer and830,...BACKGROUNDPrimary liver cancer is the sixth most prevalent tumor and the third leading cause of cancer-relatedmortality worldwide[1]. In 2020, there were approximately 900,000 new cases of primary liver cancer and830,000 associated deaths globally, with China accounting for nearly half of these cases. Hepatocellularcarcinoma (HCC) is the most common pathological type of primary liver cancer, accounting for about 90%of primary liver cancer cases in China. Over recent years, the five-year overall survival rate followinghepatectomy for resectable liver cancer has surpassed 60.0%. However, postoperative recurrence remains asignificant concern, particularly among patients classified as stage IIb and IIIa according to the China LiverCancer staging system (CNLC) in China. The one-year recurrence rates for these patients exceed 55%, whilethose with stage Ib and IIa experience recurrence rates of 32.4% and 45.7%, respectively[2].展开更多
文摘China National Logging Corporation (CNLC) is a technical service company under CNPC specializing in overseas wireline logging, mud logging, well testing, LWD/directional well and data interpretation and appraisal. To implement of CNPC's worldwide operational strategy, CNLC has actively sought for international business development and expanded the overseas service market in the principles of perfect services.
文摘目的观察原发性肝癌(primary hepatocellular carcinoma,PHC)与血清25(OH)维生素D水平的相关性。方法抽取2018年8月—2020年8月莆田市第一医院PHC患者50例作为观察组,抽取同时期健康体检者50例作为对照组。检测两组血清25(OH)D3水平以及甲胎蛋白(alpha fetoprotein,AFP)水平。结果观察组血清25(OH)D3水平低于对照组,差异有统计学意义(P<0.05)。观察组AFP水平高于对照组,差异有统计学意义(P<0.05)。PHC血清患者25(OH)D3水平与中国肝癌分期(China live cancer staging,CNLC)、淋巴结转移有关,差异有统计学意义(P<0.05)。结论针对PHC患者,其血清25(OH)D3水平主要相关因素为CNLC分期、淋巴结转移,根据血清25(OH)D3水平可为疾病治疗及其预后评估提供依据。
文摘Background and Aims:To validate prognostic performance of the China liver cancer(CNLC)staging system as well as to compare these parameters with those of the Barcelona Clinic Liver Cancer(BCLC)staging system for Chinese hepatocellular carcinoma(HCC)treated with transarterial chemoembolization(TACE).Methods:This multicenter retrospective study included 1,124 patients with HCC between January 2012 and December 2020 from six Chinese hospitals.Based on overall survival(OS),the prognostic performance outcomes for the CNLC and BCLC staging systems were compared by model discrimination[C statistic and Akaike information criterion(AIC)],monotonicity of the gradient(linear trend chi-square test),homogeneity(likelihood ratio chisquare test),and calibration(calibration plots).A prospective cohort of 44 patients receiving TACE-based therapy included between January 2021 and December 2022 was used to prospectively validate the outcomes.Results:Median OS was 19.1(18.2–20.0)months,with significant differences in OS between stages defined by the CNLC and BCLC observed(p<0.001).The CNLC performed better than the BCLC regarding model discrimination(C-index:0.661 vs.0.644;AIC:10,583.28 vs.10,583.72),model monotonicity of the gradient(linear trend chi-square test:66.107 vs.57.418;p<0.001),model homogeneity(159.2 vs.158.7;p<0.001).Both staging systems had good model calibration.Similar results were observed in the prospective cohort.Conclusions:Combining model discrimination,gradient monotonicity,homogeneity,and calibration,the CNLC performed better than the BCLC for Chinese HCC patients receiving TACE.
文摘BACKGROUNDPrimary liver cancer is the sixth most prevalent tumor and the third leading cause of cancer-relatedmortality worldwide[1]. In 2020, there were approximately 900,000 new cases of primary liver cancer and830,000 associated deaths globally, with China accounting for nearly half of these cases. Hepatocellularcarcinoma (HCC) is the most common pathological type of primary liver cancer, accounting for about 90%of primary liver cancer cases in China. Over recent years, the five-year overall survival rate followinghepatectomy for resectable liver cancer has surpassed 60.0%. However, postoperative recurrence remains asignificant concern, particularly among patients classified as stage IIb and IIIa according to the China LiverCancer staging system (CNLC) in China. The one-year recurrence rates for these patients exceed 55%, whilethose with stage Ib and IIa experience recurrence rates of 32.4% and 45.7%, respectively[2].
